The filing clarifies the full extent of Sinovac's operational damage: massive impairments on legacy COVID-era asset builds and Sinovac Chengdu, persistent net losses despite modest top-line recovery, and an almost complete distribution of retained earnings via the special dividend. The $657.9M deferred dividend payable adds overhang. With trading halted since 2019, FY2025 late filing triggering another Nasdaq delist determination (now stayed pending hearing), unresolved board legitimacy litigation in Antigua, and ongoing PIPE share disputes, the path to resuming trading is highly uncertain.
Price Chart
Executive Summary
Sinovac filed its long-delayed FY2025 annual report (20-F) on June 5, 2026, just days after receiving a Nasdaq delist notice for the same failure to file. The filing reveals deep operational deterioration: a net loss attributable to shareholders of -$59.7M (vs. +$90.9M profit in 2024), driven by $137.2M in PP&E impairments, $65.6M in goodwill/IPR&D write-offs from the Sinovac Chengdu acquisition, and a $109.8M currency loss. Revenue grew modestly to $386.0M (+6.8% YoY) on higher varicella/influenza export sales, but gross margin improvement to 67.9% was offset by operating losses of -$490.1M. A massive $3.96B dividend upstreamed from subsidiaries to Sinovac Antigua and partially distributed ($55/share special dividend) almost entirely drained retained earnings ($6.84B to $2.82B). Material weaknesses in internal controls persist. The board is still contested via ongoing Antigua SSM proceedings. Trading remains halted since Feb 2019.
Key Facts
- Net loss attributable to common shareholders of -$59.7M in FY2025 vs. net income of +$90.9M in FY2024
- Revenue grew 6.8% to $386.0M in FY2025 from $361.4M in FY2024, driven by varicella/influenza export sales
- Loss on PP&E impairment surged to $137.2M in FY2025 (vs. $30.3M in FY2024); goodwill impairment of $15.7M and IPR&D impairment of $49.8M recorded
- Cash dividend of $55.00/share declared (special dividend totaling ~$3.96B upstreamed from subsidiaries), paid $3.30B in 2025 with $657.9M deferred payable
- Retained earnings collapsed from $6.84B at Dec 2024 to $2.82B at Dec 2025
- Material weaknesses in internal controls remain unresolved — governance/financial close/ITGC weaknesses persist
- Trading halted since Feb 2019; received Nasdaq delist determination on May 22, 2026 for late filing
- Ongoing Antigua SSM Proceedings contest board legitimacy; PIPE share litigation/arbitration unresolved
- Auditor changed to Zhonghua; prior auditor (Grant Thornton) withdrew opinions for FY2021-2023 citing uncertainty over board actions
Financial Impact
Net loss of $59.7M attributable to common shareholders (vs. +$90.9M profit prior year); $386.0M revenue (+6.8%); $262.1M pre-tax loss; $137.2M PP&E impairment; $65.6M goodwill/IPR&D impairment
Risk Factors
- Nasdaq panel hearing outcome uncertain; further delist if hearing lost
- Ongoing Antigua SSM board legitimacy challenge (preliminary issues trial May-June 2026) creates governance paralysis
- PIPE litigation/arbitration could result in invalidation of 11.8M shares or cash escrow release
- Dividend withholding tax on Sinovac Hong Kong changed to 10% retroactively, increasing cash tax burden
- Cash and restricted cash at $1.16B but $657.9M is deferred dividend payable and $662.9M is escrowed for PIPE dispute
- No annual shareholder meeting held since Feb 2018 — governance vacuum persists
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 9 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 20-F Filing (Primary) | 0001193125-26-258534 |
| Document: sva-ex8_1.htm | 0001193125-26-258534 |
| Document: sva-ex12_1.htm | 0001193125-26-258534 |
| Document: sva-ex12_2.htm | 0001193125-26-258534 |
| Document: sva-ex13_1.htm | 0001193125-26-258534 |
| Document: sva-ex13_2.htm | 0001193125-26-258534 |
| Document: 0001193125-26-258534-index-headers.html | 0001193125-26-258534 |
| Document: 0001193125-26-258534-index.html | 0001193125-26-258534 |
| Document: 0001193125-26-258534.txt | 0001193125-26-258534 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 17, 2026 10w ago | 6-K | — | awaiting T+5 | — | — |
Jul 15, 2026 14w ago | 6-K | — | awaiting T+5 | — | — |
Jun 15, 2026 19w ago | 6-K | $6.47 $6.47 | · 0.00% | ▼ −2.62% | — |
Jun 5, 2026 20w ago | 20-F | $6.47 $6.47 | · 0.00% | ▲ +0.57% | — |
May 29, 2026 21w ago | 6-K | $6.47 $6.47 | · 0.00% | ▼ −2.75% | — |
May 21, 2026 22w ago | 6-K | $6.47 $6.47 | · 0.00% | ▼ −1.85% | — |
May 8, 2026 24w ago | 6-K | $6.47 $6.47 | · 0.00% | ▼ −0.09% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers